Cytosorbents Corporation (CTSO) Earnings Call Analysis

NASDAQ · Healthcare · Medical Devices

16/25

Growth 3 Margin 4 Expansion 4 Platform 3 Financial 2

latest quarter score

Earnings Reports

16
Cytosorbents (CTSO) Q2 2026: Operating Cash Burn Falls to $200K, Advancing Path to Profitability
August 08, 2026
15
Cytosorbents (CTSO) Q1 2026: Direct International Grows 13% as U.S. Regulatory Path Clarifies
May 14, 2026
16
Cytosorbents (CTSO) Q4 2025: International Sales Rise 13% as Germany Restructuring Nears Completion
March 26, 2026
16
CytoSorbents (CTSO) Q3 2025: Cost Actions Target Q1 Breakeven as Gross Margin Hits 70%
November 14, 2025
14
CTSO Q2 2025: German Sales Jump 22% as Regulatory Appeals Shape Near-Term Trajectory
August 08, 2025
14
CytoSorbents (CTSO) Q1 2025: 17% Operating Loss Improvement Amid German Market Reset
May 14, 2025
21
CytoSorbents (CTSO) Q4 2024: 25% Product Revenue Growth Fuels Near-Term Break-Even Path and U.S. Launch Readiness
March 31, 2025

Browse all companies